

**DAFTAR PUSTAKA**

- ADA. (2017). Classification and Diagnosis of Diabetes. *Diabetes Care*, 40(January), S11–S24. <https://doi.org/10.2337/dc17-S005>
- Afroz, A., Alam, K., Ali, L., Karim, A., Alramadan, M. J., Habib, S. H., Magliano, D. J., & Billah, B. (2019). Type 2 diabetes mellitus in Bangladesh: A prevalence based cost-of-illness study. *BMC Health Services Research*, 19(1), 1–12. <https://doi.org/10.1186/s12913-019-4440-3>
- Afroz, A., Alramadan, M. J., Hossain, M. N., Romero, L., Alam, K., Magliano, D. J., & Billah, B. (2018). Cost-of-illness of type 2 diabetes mellitus in low and lower-middle income countries: A systematic review. *BMC Health Services Research*, 18(1), 1–10. <https://doi.org/10.1186/s12913-018-3772-8>
- Andayani, T. M. (2006). Analisis Biaya Terapi Diabetes Melitus di Rumah Sakit Dr . Sardjito Yogyakarta. *Majalah Farmasi Indonesia*, 17(3), 130–135.
- Baroroh, F., Solikah, W. Y., & Urfiyya, Q. A. (2016). Analisis Biaya Terapi Diabetes Melitus Tipe 2 Di Rumah Sakit Pku Muhammadiyah Bantul Yogyakarta. *Jurnal Farmasi Sains Dan Praktis*, 1(2), 11–22.
- Bramer, W. M., Rethlefsen, M. L., Kleijnen, J., & Franco, O. H. (2017). Optimal database combinations for literature searches in systematic reviews: A prospective exploratory study. *Systematic Reviews*, 6(1), 1–12. <https://doi.org/10.1186/s13643-017-0644-y>
- Byford, S., Torgerson, D. J., & Raftery, J. (2000). Cost of illness studies. *Bmj*, 320(7245), 1335. <https://doi.org/10.1136/bmj.320.7245.1335>
- Cahyati, T. D. (2019). *Cost of Illness Pada Pasien Diabetes Melitus Tipe 2 Dengan Terapi Kombinasi Dua Obat Antidiabetes Oral di Beberapa Puskesmas Wilayah Surabaya*.
- Decroli, E. (2019). *Diabetes Melitus Tipe 2* (A. Kam, Y. P. Efendi, G. P.

- Decroli, & A. Rahmadi (eds.)). Pusat Penerbit Bagian Ilmu Penyakit Dalam Universitas Andalas.
- Henriksson, F., & Jönsson, B. (1998). Diabetes: The cost of illness in Sweden. *Journal of Internal Medicine*, 244(6), 461–468. <https://doi.org/10.1046/j.1365-2796.1998.00388.x>
- Henriques, R. S., Steimbach, L. M., Baptista, D. R., Lenzi, L., Tonin, F. S., Pontarolo, R., & Wiens, A. (2018). Direct Costs of Type 2 Diabetes: A Brazilian Cost-Of-Illness Study. *International Journal of Technology Assessment in Health Care*, 34(2), 180–188. <https://doi.org/10.1017/S026646231800017X>
- Higgins, M. F., Macken, A. P., Cullen, W., Saunders, J., Dunne, C., & O’Gorman, C. S. (2013). What’s the difference between PubMed and MEDLINE? And how do you best search MEDLINE anyway? *Irish Medical Journal*, 106(2 Suppl), 2–4.
- Jo, C. (2014). Cost of illness Studies : Concepts , Scopes , and Methods. *Clinical and Molecular Hepatology*, 20(4), 327–337.
- Katzung, B. G. (2012). Basic & Clinical Pharmacology. In *Annual Reports in Medicinal Chemistry* (Vol. 12). [https://doi.org/10.1016/S0065-7743\(08\)61545-6](https://doi.org/10.1016/S0065-7743(08)61545-6)
- Kitchenham, B. (2004). Procedures for Performing Systematic Reviews. *Joint Technical Report*, 1–33.
- Kristin, E. (2016). Dipeptidyl Peptidase 4 (Dpp-4) Inhibitors for the Treatment of Type 2 Diabetes Mellitus. *Journal of Thee Medical Sciences (Berkala Ilmu Kedokteran)*, 48(02), 119–130. <https://doi.org/10.19106/jmedsci004802201606>
- Lee, B. Y., Wagner, M. M., Onisko, A., & Grigoryan, V. (2006). Economic Studies In Biosurveillance. In *Handbook of Biosurveillance*. Elsevier Inc. <https://doi.org/10.1016/B978-012369378-5/50033-8>
- Malone, P. M., Kier, K. M., & Stanovich, J. E. (2006). *Literature*

- Evaluation II: Beyond the Basic*. McGraw-Hill Companies, Inc.
- Murdoch University. (2020). *Systematic Reviews - Research Guide*.  
<https://libguides.murdoch.edu.au/systematic/PICO>
- Perkeni. (2015). *Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia 2015*.
- Raich, A., & Skelly, A. (2013). Asking the Right Question: Specifying Your Study Question. *Evidence-Based Spine-Care Journal*, 04(02), 068–071. <https://doi.org/10.1055/s-0033-1360454>
- Rascati, K. L. (2014). *Essentials of Pharmacoeconomics*.
- Riskesdas. (2018). Hasil Utama Riset Kesehatan Dasar. In *Kemenkes RI*.  
<https://doi.org/10.1055/s-0033-1360454> 1 Desember 2013
- Segel, J. E. (2006). Cost of Illness Studies - A Primer. *Health Promotion Economics*, 1–39.
- Selcuk, A. A. (2019). A Guide for Systematic Reviews: PRISMA. *Turkish Archives of Otorhinolaryngology*, 57(1), 57–58.  
<https://doi.org/10.5152/tao.2019.4058>
- Sharma, K. M., Ranjani, H., Zabetian, A., Datta, M., Deepa, M., Anand Moses, C. R., Narayan, K. M. V., Mohan, V., & Ali, M. K. (2016). Excess cost burden of diabetes in Southern India: A clinic-based, comparative cost-of-illness study. *Global Health, Epidemiology and Genomics*, 1, 4–11. <https://doi.org/10.1017/gh.2016.2>
- Tharkar, S., Devarajan, A., Kumpatla, S., & Viswanathan, V. (2010). The socioeconomics of diabetes from a developing country: A population based cost of illness study. *Diabetes Research and Clinical Practice*, 89(3), 334–340. <https://doi.org/10.1016/j.diabres.2010.05.009>
- WHO. (2015). Diabetes: fakta dan angka. In *Epidemiological situation* (p. 2). <https://doi.org/https://www.who.int/leishmaniasis/burden/en/>
- Xu, X., Nardini, H. K. G., & Ruger, J. P. (2014). Micro-costing Studies in the Health and Medical Literature: Protocol for a Systematic Review.

*Systematic Reviews*, 3(1), 1–7. <https://doi.org/10.1186/2046-4053-3-47>

Xu, Z. (2003). Purchasing power parity, price indices, and exchange rate forecasts. *Journal of International Money and Finance*, 22(1), 105–130. [https://doi.org/10.1016/S0261-5606\(02\)00049-9](https://doi.org/10.1016/S0261-5606(02)00049-9)